Effect of vaccination on Bordetella pertussis strains, China

Emerging Infectious Diseases

Volumn 16, Issue 11, 2010, Pages 1695-1701

  Zhang, Liu ^a   Xu, Yinghua ^a   Zhao, Jianhong ^b   Kallonen, Teemu ^d,e   Cui, Shenghui ^a   Xu, Yunqiang ^c   Hou, Qiming ^a   Li, Fengxiang ^a   Wang, Junzhi ^a   He, Qiushui ^d   Zhang, Shumin ^a  

^a NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c Second Hospital of Shijiazhuang   (China)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; FIMBRIA 2 PROTEIN; FIMBRIA 3 PROTEIN; FIMBRIA PROTEIN; PERTACTIN; PERTACTIN 1; PERTACTIN 10; PERTACTIN 11; PERTACTIN 2; PERTACTIN 3; PERTACTIN 7; PERTUSSIS TOXIN; PERTUSSIS TOXIN A; PERTUSSIS TOXIN A1; PERTUSSIS TOXIN A2; PERTUSSIS TOXIN A3; PERTUSSIS TOXIN A4; PERTUSSIS VACCINE; TRACHEAL COLONIZATION FACTOR A PROTEIN; TRACHEAL COLONIZATION FACTOR A1 PROTEIN; TRACHEAL COLONIZATION FACTOR A2 PROTEIN; TRACHEAL COLONIZATION FACTOR A5 PROTEIN; TRACHEAL COLONIZATION FACTOR A9 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BORDETELLA PERTUSSIS; CHINA; CLUSTER ANALYSIS; DNA SEQUENCE; FIMBRIA; GENE FREQUENCY; HUMAN; NUCLEOTIDE SEQUENCE; PERTUSSIS; PULSED FIELD GEL ELECTROPHORESIS; SEROTYPE; VACCINATION;

ALLELES; BORDETELLA PERTUSSIS; FIMBRIAE PROTEINS; GENE EXPRESSION REGULATION, BACTERIAL; GENETIC VARIATION; HUMANS; PERTUSSIS TOXIN; PERTUSSIS VACCINE; SEROTYPING; TIME FACTORS; VACCINATION;

EID: 77958570417     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1611.100401     Document Type: Article

References (34)

1. Kerr JR, Matthews RC. Bordetella pertussis infection: pathogenesis, diagnosis, management, and the role of protective immunity. Eur J Clin Microbiol Infect Dis. 2000;19:77-88.DOI: 10.1007/s100960050435
2. Galanis E, King AS, Varughese P, Halperin SA; IMPACT investigators. Changing epidemiology and emerging risk groups for pertussis. CMAJ. 2006;174:451-2.DOI: 10.1503/cmaj.050379
3. Mooi FR, He Q, van Oirschot H, Mertsola J. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect Immun. 1999;67:3133-4.
4. De Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rümke HC, Conyn-van Spaendonck MA. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis. 2000;6:348-57.DOI: 10.3201/eid0604.000404
5. Caro V, Njamkepo E, Van Amersfoorth SC, Mooi FR, Advani A, Hallander HO, et al. Pulsed-fi eld gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microbes Infect. 2005;7:976-82.DOI: 10.1016/j.micinf.2005.04.005
6. Güriş D, Strebel PM, Bardenheier B, Brennan M, Tachdjian R, Finch E, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis. 1999;28:1230-7.DOI: 10.1086/514776
7. Elomaa A, Advani A, Donnelly D, Antila M, Mertsola J, Hallander H, et al. Strain variation among Bordetella pertussis isolates in Finland, where the whole-cell pertussis vaccine has been used for 50 years. J Clin Microbiol. 2005;43:3681-7.DOI: 10.1128/JCM.43.8.3681-3687.2005
8. Godfroid F, Denoël P, Poolman J. Are vaccination programs and isolate polymorphism linked to pertussis re-emergence? Expert Rev Vaccines. 2005;4:757-78.DOI: 10.1586/14760584.4.5.757
9. Elomaa A, Advani A, Donnelly D, Antila M, Mertsola J, He Q, et al. Population dynamics of Bordetella pertussis in Finland and Sweden, neighbouring countries with different vaccination histories. Vaccine. 2007;25:918-26.DOI: 10.1016/j.vaccine.2006.09.012
10. Zhang XL, Yang ZW, Zhou J, Yu JJ, Wang KA. An analysis of current epidemiological characteristics of Bordetella pertussis in China [in Chinese]. Chin J Vac Immun. 2000;6:93-5.
11. Wang J, Yang Y, Li J, Mertsola J, Arvilommi H, Shen X, et al. Infantile pertussis rediscovered in China. Emerg Infect Dis. 2002;8:859-61.
12. World Health Organization. Immunization, vaccination and biologicals. Vaccine preventable diseases monitoring system: 2009 global summary [cited 2010 Feb 26]. http://www.who.int/immunization_monitoring/en/globalsummary/countryprofileselect.cfm
13. Hallander H, Advani A, Riffelmann M, von König CH, Caro V, Guiso N, et al. Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-fi eld gel electrophoresis. J Clin Microbiol. 2007;45:3257-62.DOI: 10.1128/JCM.00864-07
14. Kallonen T, He Q. Bordetella pertussis strain variation and evolution postvaccination. Expert Rev Vaccines. 2009;8:863-75.DOI:10.1586/erv.09.46
15. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, Willems RJ. Polymorphism in the Bordetella pertussis virulence factors pertactin and pertussis toxin in the Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun. 1998;66:670-5.
16. Fry NK, Neal S, Harrison TG, Miller E, Matthews R, George RC. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect Immun. 2001;69:5520-8.DOI:10.1128/IAI.69.9.5520-5528. 2001
17. Mooi FR, Hallander H, Wirsing von König CH, Hoet B, Guiso N. Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology. Eur J Clin Microbiol Infect Dis. 2000;19:174-81.DOI: 10.1007/s100960050455
18. Xu YH, Xu YQ, Zhang SM, Wang LC, Hou QM, Lei DL. Development of fl uorescence quantitative PCR for detection of Bordetella pertussis and its application [in Chinese]. J Lab Med. 2008;6:690-4.
19. Tsang RS, Lau AK, Sill ML, Halperin SA, Van Caeseele P, Jamieson F, et al. Polymorphisms of the fi mbria fi m3 gene of Bordetella pertussis strains isolated in Canada. J Clin Microbiol. 2004;42:5364-7.DOI: 10.1128/JCM.42.11.5364-5367. 2004
20. Van Loo IH, Heuvelman KJ, King AJ, Mooi FR. Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J Clin Microbiol. 2002;40:1994-2001.DOI: 10.1128/JCM.40.6.1994-2001. 2002
21. Advani A, Donnelly D, Hallander H. Reference system for characterization of Bordetella pertussis pulsed-fi eld gel electrophoresis profi les. J Clin Microbiol. 2004;42:2890-7.DOI: 10.1128/JCM.42.7.2890-2897. 2004
22. Weber C, Boursaux-Eude C, Coralie G, Caro V, Guiso N. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol. 2001;39:4396-403.DOI: 10.1128/JCM.39.12.4396-4403. 2001
23. Caro V, Elomaa A, Brun D, Mertsola J, He Q, Guiso N. Bordetella pertussis, Finland and France. Emerg Infect Dis. 2006;12:987-9.
24. Packard ER, Parton R, Coote JG, Fry NK. Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UK. J Med Microbiol. 2004;53:355-65.DOI: 10.1099/jmm.0.05515-0
25. Lin YC, Yao SM, Yan JJ, Chen YY, Hsiao MJ, Chou CY, et al. Molecular epidemiology of Bordetella pertussis in Taiwan, 1993-2004: suggests one possible explanation for the outbreak of pertussis in 1997. Microbes Infect. 2006;8:2082-7.DOI: 10.1016/j.micinf.2006.03.019
26. Kodama A, Kamachi K, Horiuchi Y, Konda T, Arakawa Y. Antigenic divergence suggested by correlation between antigenic variation and pulsed-fi eld gel electrophoresis profi les of Bordetella pertussis isolates in Japan. J Clin Microbiol. 2004;42:5453-7.DOI: 10.1128/JCM.42.12.5453-5457. 2004
27. Guiso N, Boursaux-Eude C, Weber C, Hausman SZ, Sato H, Iwaki M, et al. Analysis of Bordetella pertussis isolates collected in Japan before and after introduction of acellular pertussis vaccines. Vaccine. 2001;19:3248-52.DOI: 10.1016/S0264-410X(01)00013-5
28. Han HJ, Kamachi K, Okada K, Toyoizumi-Ajisaka H, Sasaki Y, Arakawa Y. Antigenic variation in Bordetella pertussis isolates recovered from adults and children in Japan. Vaccine. 2008;26:1530-4.DOI: 10.1016/j.vaccine.2008.01.020
29. Chen I, Finn TM, Yanqing L, Guoming Q, Rappuoli R, Pizza M. A recombinant live attenuated strain of Vibrio cholerae induces immunity against tetanus toxin and Bordetella pertussis tracheal colonization factor. Infect Immun. 1998;66:1648-53.
30. Van Gent M, de Greeff SC, van der Heide HG, Mooi FR. An investigation into the cause of the 1983 whooping cough epidemic in the Netherlands. Vaccine. 2009;27:1898-903. DOI: 10.1016/j.vaccine.2009.01.111
31. Van Gent M, Pierard D, Lauwers S, van der Heide HG, King AJ, Mooi FR. Characterization of Bordetella pertussis clinical isolates that do not express the tracheal colonization factor. FEMS Immunol Med Microbiol. 2007;51:149-54. DOI: 10.1111/j.1574-695-X.2007.00291.x
32. Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlsson RM. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J Clin Microbiol. 2005;43:2856-65. DOI: 10.1128/JCM.43.6.2856-2865.200533.
33. Preston NW. Essential immunogens in human pertussis: the role of fi mbriae. Dev Biol Stand. 1985;61:137-41.
34. Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, Heuvelman KJ, et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis. 2009;15:1206-13.DOI: 10.3201/eid1508.081511